Kura Oncology, Inc. $KURA Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP boosted its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 130.1% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 89,303 shares of the company’s stock after purchasing an additional 50,498 shares during the period. Quantinno Capital Management LP owned approximately 0.10% of Kura Oncology worth $726,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of KURA. Suvretta Capital Management LLC grew its holdings in Kura Oncology by 5.7% during the fourth quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company’s stock worth $89,099,000 after acquiring an additional 459,422 shares during the period. Vanguard Group Inc. grew its stake in shares of Kura Oncology by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock worth $57,224,000 after purchasing an additional 39,105 shares during the period. Armistice Capital LLC increased its holdings in shares of Kura Oncology by 5.7% during the 4th quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock valued at $51,285,000 after purchasing an additional 264,000 shares in the last quarter. State Street Corp increased its holdings in shares of Kura Oncology by 47.5% during the 4th quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after purchasing an additional 1,587,959 shares in the last quarter. Finally, AQR Capital Management LLC boosted its holdings in Kura Oncology by 36.6% during the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after buying an additional 820,020 shares in the last quarter.

Insider Transactions at Kura Oncology

In other Kura Oncology news, CEO Troy Edward Wilson bought 100,000 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were acquired at an average cost of $11.12 per share, with a total value of $1,112,000.00. Following the purchase, the chief executive officer directly owned 379,194 shares of the company’s stock, valued at $4,216,637.28. This trade represents a 35.82% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Mollie Leoni sold 84,929 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total value of $834,002.78. Following the transaction, the insider owned 182,345 shares in the company, valued at approximately $1,790,627.90. This represents a 31.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on KURA. Wedbush lifted their price objective on shares of Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. Jefferies Financial Group set a $24.00 price target on Kura Oncology in a report on Thursday, May 28th. Citizens Jmp reiterated a “market outperform” rating and set a $24.00 price target on shares of Kura Oncology in a research report on Monday, June 15th. Oppenheimer set a $24.00 price objective on Kura Oncology in a research report on Thursday, May 28th. Finally, CLSA set a $24.00 target price on Kura Oncology in a research report on Thursday, June 4th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $25.62.

Kura Oncology Price Performance

NASDAQ:KURA opened at $12.33 on Wednesday. The stock has a 50 day moving average of $10.34 and a two-hundred day moving average of $9.39. Kura Oncology, Inc. has a 12 month low of $6.95 and a 12 month high of $12.85. The firm has a market cap of $1.09 billion, a P/E ratio of -3.66 and a beta of 0.38. The company has a current ratio of 4.73, a quick ratio of 4.71 and a debt-to-equity ratio of 0.12.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The firm had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. On average, analysts expect that Kura Oncology, Inc. will post -3.23 earnings per share for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.